Back to top
more

Progyny (PGNY)

(Real Time Quote from BATS)

$13.48 USD

13.48
248,923

-0.50 (-3.58%)

Updated Nov 15, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (141 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

MD vs. PGNY: Which Stock Is the Better Value Option?

by Zacks Equity Research

MD vs. PGNY: Which Stock Is the Better Value Option?

What Makes Progyny (PGNY) a New Buy Stock

by Zacks Equity Research

Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Should You Buy Progyny (PGNY) After Golden Cross?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Looking for a Growth Stock? 3 Reasons Why Progyny (PGNY) is a Solid Choice

by Zacks Equity Research

Progyny (PGNY) possesses solid growth attributes, which could help it handily outperform the market.

Earnings Estimates Moving Higher for Progyny (PGNY): Time to Buy?

by Zacks Equity Research

Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

How Much Upside is Left in Progyny (PGNY)? Wall Street Analysts Think 32.32%

by Zacks Equity Research

The consensus price target hints at a 32.3% upside potential for Progyny (PGNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Progyny (PGNY) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Progyny (PGNY) delivered earnings and revenue surprises of 125% and 5.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Progyny (PGNY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Progyny (PGNY) delivered earnings and revenue surprises of 50% and 1.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Premier, Inc. (PINC) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 7.46% and 0.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays

by Zacks Equity Research

Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.

Sanghamitra Saha headshot

In Search of an Earnings Beat? Play These Top 5 Stocks

by Sanghamitra Saha

These top-ranked stocks are likely to beat on bottom line in their next releases. Tap Yum China (YUMC), Impinj (PI), Five Below (FIVE), Hologic (HOLX) and Progyny (PGNY).

Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe

by Zacks Equity Research

Edwards Lifesciences (EW) continues to witness strong momentum of the RESILIA portfolio globally.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.

Encompass Health's (EHC) Plan Marks Entry in Rhode Island

by Zacks Equity Research

Encompass Health (EHC) aims to build a 50-bed inpatient rehabilitation hospital in Rhode Island and extend its advanced rehabilitative services suite across the Northeast.

Here's Why Investors Should Retain Globus Medical (GMED) Stock

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) robust performance across several international markets.

UnitedHealth (UNH) Unit Ties Up to Boost Care in Two U.S. Regions

by Zacks Equity Research

UnitedHealth Group's (UNH) subsidiary Optum aims to advance organizational efficiencies of Owensboro Health and bring about better health outcomes in western Kentucky and southern Indiana.

Molina Healthcare (MOH) to Incur $200M Impairment Charge in Q4

by Zacks Equity Research

The reduction of Molina Healthcare's (MOH) real estate footprint is expected to result in a sizeable decline in leased real estate expense.

Humana (HUM) Subsidiary Wins $70.8B DoD East Region Contract

by Zacks Equity Research

The latest award marks Humana's (HUM) military subsidiary's sixth TRICARE contract win.

Here's What You Should Know From Centene's (CNC) 2023 Outlook

by Zacks Equity Research

Centene's (CNC) board boosts its share buyback program with a new $2-billion fund.

ELV vs. PGNY: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. PGNY: Which Stock Is the Better Value Option?

Sanghamitra Saha headshot

Looking for Earnings Beat? Buy These 5 Stocks With Potential

by Sanghamitra Saha

These top-ranked stocks -- Chewy (CHWY), Progyny (PGNY), KnowBe4 (KNBE), Chegg (CHGG) and Fortinet (FTNT) -- are likely to beat on their bottom line in the next releases.

Zacks Industry Outlook Highlights Medpace, HealthEquity and Progyny

by Zacks Equity Research

Medpace, HealthEquity and Progyny have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy Amid Industry Challenges

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and PGNY are set to gain the most. However, staffing shortages may disrupt the trend.

Cigna (CI) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Cigna's (CI) stock price is increasing on the back of solid performances in the Evernorth and Cigna Healthcare businesses.